-+ 0.00%
-+ 0.00%
-+ 0.00%

Context Therapeutics Announces Amendment To Its Exclusive License Agreement With BioAtla To Remove All Future Milestone And Royalty Obligations For CT-202 In Exchange For A $4.5M Upfront Payment And A Final $2M Payment Due By August 1

Benzinga·05/18/2026 10:49:09
Listen to the news

Phase 1 initiation for CT-202 trial expected in third quarter of 2026